Compugen Ltd. (NASDAQ: CGEN) will present a trial-in-progress poster on its MAIA-ovarian Phase 1 study at the ESMO Gynaecological Cancers Congress 2026, according to a company statement.

The poster presentation will take place June 18, 2026, from 12:45 to 13:30 CEST in Copenhagen, Denmark. Dr. Oladapo Yeku from Massachusetts General Hospital in Boston will present the data.

The MAIA-ovarian study evaluates COM701, an anti-PVRIG antibody, as maintenance treatment in patients with relapsed platinum-sensitive ovarian cancer. The trial is registered under NCT06888921 and represents an adaptive platform clinical trial design.

COM701 is being developed as a potential treatment for solid tumors and has been studied both as a single agent and in combination therapies. The company describes it as a potential first-in-class anti-PVRIG antibody.

Compugen is a clinical-stage cancer immunotherapy company based in Holon, Israel, that uses computational methods powered by artificial intelligence and machine learning to identify drug targets. The company's pipeline includes four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321.

Following the congress presentation, the poster will be made available on Compugen's website. The ESMO Gynaecological Cancers Congress runs from June 17 to June 19, 2026.